Group 1 - Suzhou Rebio Technology Co., Ltd. successfully listed on the Hong Kong Stock Exchange on January 9, becoming the first listed company in Jiangsu province this year [1] - The company issued 31.61 million shares at a price of HKD 57.97 per share, raising over HKD 1.8 billion in total [1] - Rebio, founded in 2007 and headquartered in Suzhou, focuses on the research and development of small nucleic acid drugs, utilizing RNA interference (RNAi) technology to develop innovative therapies for major diseases [1] Group 2 - Rebio's research pipeline covers various diseases, particularly chronic diseases, with seven self-developed drugs currently in clinical trials, four of which are in Phase II [1] - The core product, RBD4059, is the world's first clinical-stage small nucleic acid drug for treating thrombotic diseases, offering significant advantages over traditional treatments, such as extended efficacy and lower bleeding risks [1] - With Rebio's listing, the number of companies listed from Suzhou on the Hong Kong Stock Exchange has increased to 42, further expanding the biopharmaceutical sector in the region [2]
新年江苏“第一股”！瑞博生物在港交所上市